Takeda Builds on 30-Year Partnership with the World Federation of Hemophilia with a Five-Year Product Donation to the Humanitarian Aid Program

March 29, 2021

Program Aims to Help Advance the Standard of Care for People with Inherited Bleeding Disorders in Developing Countries

Osaka, Japan, March 29, 2021 – Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”) today announced it has joined the World Federation of Hemophilia’s (WFH) Humanitarian Aid Program with a five-year product donation of coagulation factor and bypassing agents. The WFH’s Humanitarian Aid Program seeks to improve the lack of access to care and treatment for people with inherited bleeding disorders in developing countries.¹ This donation builds on a 30-year partnership with the WFH, driven by Takeda’s belief that every bleed matters and that all men and women with a rare bleeding disorder, wherever they live, should have access to comprehensive, personalized care.

“At Takeda we recognize the need to advance the standard of care for those living with a rare bleeding disorder, as well as the importance of tackling disparities in access to treatment worldwide. To achieve these ambitions, we have to work together as a community and focus on evidence-based advocacy,” said Julie Kim, president of the Plasma-Derived Therapies Business Unit of Takeda. “This five-year product donation aims to help the WFH in improving access to treatment, including prophylaxis to protect joint health. We are pleased to be able to continue collaborating with the WFH on their flagship advocacy and data collection programs, supporting our ambition to achieve a world without bleeds.”

The WFH and its national member organizations have made significant progress in improving diagnosis and access to care through programs such as the World Bleeding Disorder Registry (WBDR) and the Global Alliance for Progress (GAP) program, both of which are supported by Takeda. The WBDR provides a platform for hemophilia treatment centers around the world to collect standardized patient data to help guide clinical practice. It began in 2018 and has a five-year goal of enrolling 10,000 people with hemophilia across 50 countries.² The GAP program aims to close the gap between developed and developing countries in the diagnosis and treatment of people with hemophilia and other bleeding disorders by working with local systems and infrastructures to maximize existing resources and achieve long-term sustainable development.³ Takeda has been a visionary partner and strong supporter of the GAP program since it was launched in 2003. These programs along with the Humanitarian Aid Program strive to advance the standard of care for patients with hemophilia and other bleeding disorders through evidence-based advocacy.

“Takeda has collaborated with the WFH for over 30 years, playing an important role in several of our programs, including the GAP Program and the WBDR,” said Alain Baumann, CEO of the WFH. “We are thankful that Takeda has now extended their support to the WFH Humanitarian Aid Program. This will allow the WFH to do even more to support bleeding disorders communities in need around the world.”

###

About Takeda Hematology

Following its recent acquisition of Shire, Takeda is a leader in rare hematology with the longest heritage and market-leading portfolio, backed by established safety and efficacy profiles with decades of real-world experience. We have 70+ years driving innovation for patients⁴ and a broad portfolio of 11 products across multiple bleeding disorders.⁵ Our experience as leaders in hematology means we are well prepared to meet today’s needs as we pursue future developments in the care of bleeding disorders. Together with the hematology community, we are raising expectations for the future, including earlier diagnosis, earlier and full protection against bleeds, and more personalized patient care.

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries. For more information, visit https://www.takeda.com.

Media Contacts:

Japanese Media
Kazumi Kobayashi
[email protected]
+81 (0) 3-3278-2095

Media Outside Japan
Emily Bunting
[email protected]
+41 79 866 97 03

Important Notice

For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws.

The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.

Forward-Looking Statements

This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could” “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/reports/sec-filings/ or at www.sec.gov. Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results.

¹World Federation of Hemophilia World Bleeding Disorders Registry. World Federation of Hemophilia website. Available at: https://bit.ly/37qbBSs. Last accessed March 2021.

²World Federation of Hemophilia Humanitarian Aid Program. World Federation of Hemophilia website. Available at: https://bit.ly/2M0Ee15. Last accessed March 2021.

³ World Federation of Hemophilia Global Alliance for Progress Program. World Federation of Hemophilia website. Available at: https://bit.ly/3seDViA. Last accessed March 2021.

⁴ Takeda Website. Rare Diseases. Available at: https://bit.ly/3n9gvIN. Last accessed March 2021.

⁵ Takeda Website. U.S. Product List. Available at: https://bit.ly/35a6HYF. Last accessed March 2021.